All In MedTech

Device Trial Radar · NCT06114992

Servo-n HFOV Study: Safety and Performance in Neonates and Infants

Servo-n High-Frequency Oscillatory Ventilation in Clinical Practice: A Prospective, Observational, Single-arm and Multi-center Study

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Jul 15, 2024

Primary completion

Apr 14, 2026

Study completion Jul 3, 2026

Sponsor

Lead sponsor
Maquet Critical Care ABNot on our public-company list
Sponsor type
Industry
Collaborators
NAMSA; Paediatric and Neonatal Mechanical Ventilation (PNV) Consulting
First posted
Nov 2, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and performance of High-Frequency Oscillatory Ventilation (HFOV) modes of the Servo-n ventilator in neonates and infants, by using a prospective, observational, single-arm (i.e., non-controlled) and multi-center Post-Market Follow-up (PMCF) study design. HFOV treatment will be evaluated by assessing ventilation and oxygenation variables, and safety will be evaluated by documentation of device related adverse events.

Conditions

  • Elective HFOV for Respiratory Failure in Neonates/Infants
  • Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy

Interventions

  • Servo-n HFOV modesDevice

    Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects that achieved and/or maintained target ranges for oxygenation, as measured by preductal Saturation of Peripheral Oxygen (SpO2).Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
  2. Proportion of subjects that achieved and/or maintained target ranges for ventilation as measured either by Partial Pressure of Carbon Dioxide (PCO2) (if available blood gas) or Transcutaneous Carbon Dioxide (TcCO2)Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
  3. Proportion of subjects that maintained or improved values for oxygenation as measured by the SpO2/FiO2 ratio and/ or achieved target ranges for oxygenation (preductal SpO2)Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days

1 more outcomes with a free account

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • CHU Montpellier-Arnaud de Villeneuve

    Montpellier, France

  • Antoine-Béclère Hospital

    Paris, France

  • Poznan University of Medical Sciences

    Poznan, Poland

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.